Novo Nordisk
2022-02-02T06:30:38Z
2022-02-02T06:30:38Z
Financial report for the period 1 January 2021 to 31 December 2021
PROFIT AND LOSS | 2021 | 2020 | Growth as reported | Growth at CER* |
DKK million | ||||
Net sales | 140,800 | 126,946 | 11% | 14% |
Operating profit | 58,644 | 54,126 | 8% | 13% |
Net profit | 47,757 | 42,138 | 13% | N/A |
Diluted earnings per share (in DKK) | 20.74 | 18.01 | 15% | N/A |
* CER: Constant exchange rates (average 2020).
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the double-digit sales growth in 2021 and the progress we have made on our Strategic Aspirations. The results reflect that almost 35 million people with diabetes are now benefiting from our treatments worldwide. In obesity, we are making progress in resolving the Wegovy® supply issue and we expect to be able to meet demand from people living with obesity in the US in the second half of 2022".
On 2 February 2022 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Financial calendar | |
3 March 2022 | Capital Markets Day in Copenhagen, Denmark |
24 March 2022 | Annual General Meeting |
4 May 2022 | Financial statement for the first three months of 2022 |
4 August 2022 | Financial statement for the first six months of 2022 |
2 November 2022 | Financial statement for the first nine months of 2022 |
Contacts for further information | ||
Media: | ||
Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com |
Michael Bachner (US) | +1 609 664 7308 | mzyb@novonordisk.com |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
David Heiberg Landsted | +45 3077 6915 | dhel@novonordisk.com |
Jacob Martin Wiborg Rode | +45 3075 5956 | jrde@novonordisk.com |
Mark Joseph Root (US) | +1 848 213 3219 | mjhr@novonordisk.com |
Company announcement No 7 /2022
Attachment